menu
    • menu
    [{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius Kabi AG \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Premier"},{"orgOrder":0,"company":"Avet Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avet Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Avet Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avet Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amneal Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hospira, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Hospira, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hospira, Inc.","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Hospira, Inc. \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Hospira, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Propofol","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Rapinovet

    Menu

    Rapinovet

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avenacy

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Avenacy

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avenacy Announces Launch of Propofol Injectable Emulsion, USP in the U.S. Market

                            Details : Diprivan-Generic (propofol) is an intravenous general anesthetic and sedation drug indicated for induction of general anesthesia.

                            Product Name : Diprivan-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 07, 2025

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Amneal Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amneal Receives U.S. FDA Approval For Propofol Injectable Emulsion Single Dose Vials

                            Details : Diprivan-Generic (propofol) is approved in the US, which is an intravenous drug commonly used in hospitals for the induction and maintenance of anesthesia and sedation.

                            Product Name : Diprivan-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 20, 2024

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hospira, Inc.

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Hospira, Inc.

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion (containing benzyl al...

                            Details : Propofol is an intravenous general anesthetic and sedation drug for use in the induction and maintenance of anesthesia or sedation. Propofol Injectable Emulsion is a terminally sterilized (TS) product.

                            Product Name : Propofol-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 22, 2022

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hospira, Inc.

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Hospira, Inc.

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hospira Issues A Voluntary Nationwide Recall For One Lot of Propofol Injectable Emulsion, USP (Containing Benz...

                            Details : Propofol is an intravenous general anesthetic and sedation drug for use in the induction and maintenance of anesthesia or sedation. Propofol Injectable Emulsion, USP is a terminally sterilized (TS) product.

                            Product Name : Propofol-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 13, 2022

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Avet Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed

                            Avet Pharmaceuticals

                            U.S.A arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avet Pharmaceuticals Announces Approval and Launch of Propofol Injectable Emulsion, USP

                            Details : Propofol injectable emulsion, an AB-rated generic equivalent of DIPRIVAN® (propofol) Injectable Emulsion USP is an intravenous general anesthetic and sedation drug indicated for initiation and maintenance of Monitored Anesthesia Care (MAC) sedation.

                            Product Name : Propofol-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 04, 2022

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Fresenius Kabi AG

                            Germany arrow
                            AAN
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            AAN
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Premier

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential...

                            Details : Premier through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize the long-term supply of a medication vital for COVID-19 patient care.

                            Product Name : Diprivan

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 13, 2020

                            Lead Product(s) : Propofol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Premier

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth